Publications by authors named "Maria Cristina Carraro"
Article Synopsis
- Up to 30% of chronic myeloid leukemia (CML) patients may need a treatment change due to issues with first-line tyrosine kinase inhibitors (TKIs), and bosutinib (BOS) emerges as an effective and safe alternative.
- A study analyzed 132 CML patients treated with BOS across 18 hematology centers, finding that most patients switched due to intolerance to previous TKIs, with a significant number achieving positive treatment outcomes.
- The findings suggest that BOS is a preferred treatment choice, particularly for patients who cannot tolerate previous TKIs, demonstrating its safety and effectiveness in real-life settings.
Article Synopsis
- Ruxolitinib (RUX) is a treatment for myelofibrosis (MF) but often loses effectiveness over time, leading to worse overall survival after stopping treatment.
- The study identified key predictors of survival for RUX-treated MF patients, such as dose, spleen size change, and need for blood transfusions after 6 months of treatment.
- A new prognostic model called Response to Ruxolitinib After 6 Months (RR6) was developed, categorizing patients into low, intermediate, and high-risk groups for survival, helping guide treatment decisions.
Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia.
Antiinflamm Antiallergy Agents Med Chem
January 2022
Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.
Case Presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years.
Chronic Myeloid Leukemia is a clonal disorder characterized by the presence of the Ph-chromosome and the BCR-ABL tyrosine-kinase (TK). Target-therapy with Imatinib has greatly improved its outcome. Deeper and faster responses are reported with the second-generation TKI Nilotinib.
View Article and Find Full Text PDFBackground: Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic formulations are contrasting. The aim of this study was to investigate the safety and efficacy of generic imatinib in CML patients treated in 12 Italian institutes.
View Article and Find Full Text PDFWe present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years. We found no evidence of an increased risk of developing lymphomas.
View Article and Find Full Text PDFNilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.
PLoS One
February 2020
Article Synopsis
- * A study analyzed gene expression in bone marrow cells of CML patients before and after 12 months of nilotinib treatment, identifying significant changes in gene expression and specific pathways affected by the therapy.
- * Notably, the study found down-regulation of genes related to the cell cycle and specific ABC transporters, which may contribute to the cells' ability to resist the drug, as well as changes in genes involved in the J
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.
Cancer Biomark
December 2017
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.
Objective: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.